Theory Paper IIDrNB Cardiology – Theory Notes

ACUTE PULMONARY EMBOLISM (PE)

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITION AND THE “SPIRAL OF DEATH” PATHOPHYSIOLOGY

  • Definition: Acute Pulmonary Embolism (PE) is the mechanical and vasoconstrictive obstruction of the pulmonary arterial tree by a thromboembolus (originating in 80 to 90 percent of cases from proximal Deep Vein Thrombosis [DVT] of the iliofemoral or popliteal veins).
  • The Right Ventricular “Spiral of Death” (ESC 2019):
    • Abrupt Afterload Spike: Mechanical occlusion of >30 to 50 percent of the pulmonary vascular bed combined with platelet release of Thromboxane A2 and Serotonin causes an abrupt surge in Pulmonary Vascular Resistance (PVR).
    • RV Dilatation and Ventricular Interdependence: Because the thin-walled, unconditioned Right Ventricle (RV) cannot acutely generate a mean PA pressure above 40 mmHg (Peak RVSP >60 mmHg suggests chronic pre-existing PH), the RV dilates acutely, stretching the tricuspid annulus (causing functional TR) and shifting the interventricular septum leftward into the Left Ventricle (“D-shaped LV”) within the rigid pericardium—impairing LV diastolic filling (underloading) and dropping systemic cardiac output.
    • RV Myocardial Ischemia and Obstructive Shock: Elevated RV wall tension compresses the intramuscular branches of the Right Coronary Artery (RCA) while systemic arterial hypotension reduces aortic root coronary perfusion pressure, precipitating RV myocardial ischemia/infarction, cardiovascular collapse, and Pulseless Electrical Activity (PEA) arrest.

IIDIAGNOSTIC PROBABILITY SCORES AND D-DIMER ALGORITHMS

  • Pre-Test Probability Clinical Prediction Rules (Applied BEFORE Imaging):
    • Wells Score for PE: Clinical signs/symptoms of DVT (3.0 pts), PE is #1 diagnosis or equally likely (3.0 pts), Heart rate >100 bpm (1.5 pts), Immobilization >=3 days or surgery in prior 4 weeks (1.5 pts), Previous objectively diagnosed DVT or PE (1.5 pts), Hemoptysis (1.0 pt), and Malignancy treated within 6 months or palliative (1.0 pt). Two-Level Cut-off: Score <=4.0 = “PE Unlikely” (order high-sensitivity D-dimer); Score >4.0 = “PE Likely” (proceed directly to CTPA).
    • Revised Geneva Score: Fully objective 8-variable score (excludes the subjective “PE more likely” item).
    • PERC Rule (Pulmonary Embolism Rule-Out Criteria): Applied only when pre-test probability is low (<15%); if all 8 criteria are negative (Age <50 yr, HR <100 bpm, SpO2 >=95% on room air, no hemoptysis, no exogenous estrogen use, no prior DVT/PE, no surgery/trauma requiring hospitalization within 4 weeks, no unilateral leg swelling), PE is safely excluded without ordering a D-dimer.
    • Specificity-Enhanced D-Dimer Rules (Class IIa):
    • Age-Adjusted D-Dimer: In patients over 50 years of age with non-high pre-test probability, the normal D-dimer cut-off of 500 ng/mL (ug/L) is replaced by Age (in years) x 10 ng/mL (e.g., 750 ng/mL in a 75-year-old).
    • YEARS Algorithm: Assesses 3 items (Clinical signs of DVT, Hemoptysis, PE most likely diagnosis): if 0 YEARS items are present, PE is excluded if D-dimer <1,000 ng/mL; if >=1 YEARS item is present, PE is excluded if D-dimer <500 ng/mL.
    • Pregnancy-Adapted YEARS Algorithm (NEJM 2019 / ESC Class IIa): Combines proximal lower-extremity compression ultrasonography (if DVT symptoms exist) with the 3 YEARS criteria + variable D-dimer (<1,000 ng/mL if 0 items; <500 ng/mL if >=1 item), safely avoiding CTPA radiation in 39 to 65 percent of pregnant women.

IIIPROGNOSTIC RISK STRATIFICATION (ESC 2019 FOUR-TIER MODEL)

  • Abandonment of “Massive / Submassive”: Replaced by the ESC 4-Tier Risk Classification integrating (1) Hemodynamic Stability, (2) Clinical Severity (PESI Class III–V or sPESI >=1), (3) Right Ventricular Dysfunction on TTE or CTPA, and (4) Elevated Cardiac Troponin (hs-cTnI/T):
  • Simplified PESI (sPESI — 1 Point Each; Score 0 = Low Risk [~1.0% 30-day mortality]; Score >=1 = High Risk [~10.9% mortality]): Age >80 years, History of Cancer, Chronic Cardiopulmonary Disease (HF or COPD), Heart Rate >=110 bpm, Systolic BP <100 mmHg, and Arterial SpO2 <90%.
  • Bova Score (0 to 7 Points for Normotensive PE Sub-Stratification): SBP 90–100 mmHg (2 pts), Elevated cardiac troponin (2 pts), RV dysfunction on Echo or CTPA (2 pts), and Heart rate >=110 bpm (1 pt); Stage III (>4 points) predicts a >25 to 40 percent risk of 30-day PE-related complications/hemodynamic collapse.
ESC Risk Category Shock or Hypotension PESI Class III–V or sPESI >=1 RV Dysfunction (TTE or CTPA) Elevated Cardiac Troponin Primary First-Line Management Strategy (ESC Class I)
High-Risk PE (~5% of PE; >15–30% mortality) YES (Arrest, obstructive shock, or persistent SBP <90 mmHg) (+) YES (+) Immediate IV UFH + Systemic Thrombolysis (Class I) (or Surgical/Catheter Embolectomy if lytics contraindicated)
Intermediate-High Risk No YES YES (Both Present) YES (Both Present) Parenteral/Oral Anticoagulation + ICU/Telemetry Monitoring; Rescue Reperfusion / CDT if deterioration (PEITHO)
Intermediate-Low Risk No YES Either One Positive (or Both Negative) Either One Positive (or Both Negative) Inpatient Anticoagulation (LMWH/Fondaparinux -> DOAC)
Low-Risk PE (~1% mortality) No NO (PESI I–II / sPESI = 0) NO NO Direct Oral Anticoagulant (DOAC) + Early Discharge (<24–48 h) / Home Treatment (Class IIa — HoT-PE)

IVOBJECTIVE ECHOCARDIOGRAPHIC AND CTPA SIGNS OF RV DYSFUNCTION

  • Bedside Transthoracic Echocardiography (Mandatory First Test in Unstable Suspected PE):
    • RV/LV Basal End-Diastolic Diameter Ratio >= 1.0 with interventricular septal flattening (D-sign).
    • McConnell Sign: Akinesia of the mid-free wall of the RV with preserved (normokinetic/hyperkinetic) apical contractility (high specificity >94% for acute PE, though also seen in RV infarction).
    • The “60/60 Sign”: Coexistence of a shortened Pulmonary Acceleration Time (PAT) <60 ms (with mid-systolic notching of the RVOT pulsed-wave Doppler envelope) and a Tricuspid Regurgitation Peak Systolic Gradient <60 mmHg (confirming acute pressure load on an unconditioned RV).
    • Decreased TAPSE (<16 mm): Independently predicts PE-related mortality.
    • Right Heart Thrombus-in-Transit: Mobile serpentine thrombus in the RA/RV or straddling a PFO (present in 4%; carries >20% mortality).
    • CT Pulmonary Angiography (CTPA — Diagnostic Gold Standard): Direct intraluminal filling defect (“saddle” or lobar/segmental embolus) with an RV/LV diameter ratio >= 0.9 to 1.0 on 4-chamber view and contrast reflux into the IVC/hepatic veins.

VEVIDENCE-BASED MANAGEMENT AND LANDMARK CLINICAL TRIALS

  • Hemodynamic Support in RV Obstructive Shock:
    • Judicious Fluid Challenge (<=500 mL Only): Give no more than 500 mL of isotonic crystalloid over 15 to 30 minutes only in patients with low central venous pressure; aggressive volume loading over-distends the RV, shifts the septum further into the LV, increases RV wall stress/ischemia, and worsens shock.
    • Vasopressors and Inotropes: Norepinephrine (0.1 to 1.0 mcg/kg/min) is the first-line vasopressor (restores aortic root RCA perfusion pressure and improves systemic RV-LV interaction), supplemented with Dobutamine (2 to 10 mcg/kg/min) or Inhaled Nitric Oxide if cardiac output remains low; VA-ECMO serves as a bridge to surgical or mechanical embolectomy in refractory cardiac arrest/shock.
    • Anticoagulation Regimens (Class I):
    • Parenteral: LMWH (Enoxaparin 1 mg/kg SC q12h) or Fondaparinux is preferred over Unfractionated Heparin (UFH: 80 U/kg bolus + 18 U/kg/h) except in High-Risk PE with shock, severe renal failure (CrCl <30 mL/min), or severe obesity.
    • First-Line Single-Drug DOAC Regimens (AMPLIFY & EINSTEIN-PE Trials): Apixaban (10 mg BD for 7 days, then 5 mg BD) or Rivaroxaban (15 mg BD for 21 days with food, then 20 mg OD) (whereas Dabigatran 150 mg BD and Edoxaban 60 mg OD require 5 days of initial parenteral heparin). (DOACs are contraindicated in pregnancy, severe renal failure, and triple-positive Antiphospholipid Syndrome.)
    • Extended Secondary Prevention (>6 Months — AMPLIFY-EXT & EINSTEIN CHOICE Trials): After 6 months of treatment for unprovoked PE, reduced-dose Apixaban 2.5 mg BD or Rivaroxaban 10 mg OD reduces recurrent VTE by ~80 percent without increasing major bleeding.
    • Systemic Thrombolysis and Catheter-Directed Therapies (CDT):
    • High-Risk PE (Class I): Alteplase (rt-PA) 100 mg IV over 2 hours (or 0.6 mg/kg [max 50 mg] over 15 minutes / 50 mg IV bolus in cardiac arrest).
    • PEITHO Trial (NEJM 2014 — Why Routine Lytics are Class III in Intermediate-High Risk PE): In 1,005 normotensive Intermediate-High Risk PE patients, weight-based Tenecteplase reduced 7-day death or hemodynamic collapse (2.6% vs. 5.6%; p = 0.02), but caused a 5-fold increase in major extracranial bleeding (6.3% vs. 1.2%) and a 10-fold increase in hemorrhagic/ischemic stroke (2.4% vs. 0.2%) with zero difference in 30-day mortality or late CTEPH—restricting systemic thrombolysis in intermediate-risk PE strictly to rescue therapy if hemodynamic decompensation occurs.
    • Catheter-Directed Therapies (ULTIMA, OPTALYSE-PE, FLARE/FLASH, and PEERLESS Trials): Ultrasound-Facilitated Catheter-Directed Thrombolysis (USCDT / EKOS: 4 to 12 mg total Alteplase per lung) (ULTIMA, OPTALYSE-PE) and Large-Bore Mechanical Aspiration Thrombectomy (FlowTriever / Indigo) (FLARE, FLASH) rapidly reverse RV/LV dilation with <1.5% major bleeding. In the head-to-head randomized PEERLESS Trial (Circulation 2024, n = 550 intermediate-high risk PE), Large-Bore Mechanical Thrombectomy (FlowTriever) proved superior to Catheter-Directed Thrombolysis for the primary hierarchical win-ratio endpoint (driven by significantly fewer clinical deteriorations/bailouts [1.8% vs. 5.4%] and less ICU admission/length of stay, with similar mortality and intracranial bleeding).
    • Post-PE Syndrome and CTEPH Screening (Class I): Every acute PE survivor must be evaluated at 3 to 6 months post-PE; persistent dyspnea or functional limitation warrants Transthoracic Echocardiography and a Ventilation/Perfusion (V/Q) lung scan (not CTPA alone) to rule out Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Key references

  • Konstantinides SV, Meyer G, Becattini C, et al.: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism, European Heart Journal, 2020.
  • Meyer G, Vicaut E, Danays T, et al. (PEITHO Investigators): Fibrinolysis for patients with intermediate-risk pulmonary embolism, New England Journal of Medicine, 2014.
  • Jaber WA, Gonsalves CF, Stortecky S, et al. (PEERLESS Investigators): Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial, Circulation, 2024.
  • Barco S, Schmidtmann I, Ageno W, et al. (HoT-PE Investigators): Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial, European Heart Journal, 2020.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.